Verona signs Chi­na deal for PhI­II COPD drug; Te­va con­tin­ues le­gal bat­tle with Eli Lil­ly, al­leg­ing new patent in­fringe­ments on mi­graine drug

Af­ter a Feb­ru­ary Phase II win put Verona’s bad mem­o­ries of a 2019 flop be­hind them, the com­pa­ny is now en­gag­ing in part­ner­ships to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.